Develops small molecule therapeutics for cystic fibrosis (CF). Focuses on normalizing the function of the CFTR protein. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $235.9M in the vault; even if every debt were paid off, $227.2M would remain.
A loss of $75.3M against $0 in annual sales.
Over the last 12 months, executives reported 151 sells against just 25 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, SION sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SION is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (45/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.